EWA
IMMU

Exencial Wealth Advisors’s Immunomedics Inc IMMU Stock Holding History

Exencial Wealth Advisors’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-15,172
Closed -$217K – 235
2018
Q4 		$217K Buy
+15,172
New +$301K 0.06% 192

Other funds holding IMMU

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Exencial Wealth Advisors's IMMU Position: Q1 2019 in Review

Exencial Wealth Advisors sold out of Immunomedics Inc (IMMU) in Q1 2019, closing a stake of 15,172 shares — an estimated $217K sold.

Exencial Wealth Advisors first reported a position in IMMU in Q4 2018 and held it in 1 quarter. The position peaked at $217K in Q4 2018. 204 funds tracked by Wall St. Rank hold IMMU as of Q1 2019.

  • Exencial Wealth Advisors reported no remaining Immunomedics Inc position as of Q1 2019 after selling out during the quarter.
  • Exencial Wealth Advisors sold 15,172 Immunomedics Inc shares in Q1 2019, an estimated $217K.
  • Exencial Wealth Advisors first reported a position in Immunomedics Inc in Q4 2018 and held it in 1 quarter.
  • Exencial Wealth Advisors's Immunomedics Inc position peaked at $217K in Q4 2018.
  • 204 funds tracked by Wall St. Rank held Immunomedics Inc as of Q1 2019.

Based on Exencial Wealth Advisors's 13F filing for Q1 2019, filed 8 May 2019.